Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
List view / Grid view
News
Blood test can identify COVID-19 patients at high risk of life-threatening complications
The rapid blood test could be used to identify hospitalised COVID-19 patients who may benefit from investigational treatments and early interventions.
UK vaccine supply chain workers to be offered COVID-19 jabs
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
Israel set to be first country to vaccinate entire population against COVID-19
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
New system could deliver schizophrenia medicine directly to brain
A team has created a nasal spray as a drug delivery system to get schizophrenia medication directly to the brain.
Japan has pre-ordered COVID-19 vaccine doses for more than four times its population, says report
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
FDA approves crizotinib for children with certain anaplastic large cell lymphomas
In a Phase I/II trial, 81 percent of paediatric patients with relapsed or refractory, systemic anaplastic large cell lymphoma achieved complete remission with crizotinib (Xalkori).
Optimising a panel for microbiologic diagnosis of pneumonia
Researchers studying the microbiologic diagnosis of pneumonia have identified ways to optimise a pneumonia panel.
Trial to evaluate inhaled COVID-19 therapy finishes enrolment
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
US could purchase over 1.5 million doses of Regeneron’s COVID-19 antibody cocktail
The additional doses of casirivimab and imdevimab, two monoclonal antibodies, will be used in non-hospitalised COVID-19 patients.
Pharma industry employs 5,600 people in Scotland, report says
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
Baricitinib and remdesivir reduce time to recovery in COVID-19 patients
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.
Valneva may provide Europe with the only inactivated virus vaccine for COVID-19
The Europe Commission is currently in discussions to procure millions of doses of Valneva’s COVID-19 innactivated virus vaccine, VLA2001.
UK could “become the world’s foremost nation for drug security,” says FarmaTrust
The global medical authentication provider is urging the government to secure the UK’s medicines supply by modernising the system with blockchain technologies.
